A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of VT-1161 in Healthy Japanese and Western Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of VT-1161 in Healthy Japanese and Western Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs VT 1161 (Primary)
  • Indications Onychomycosis; Vulvovaginal candidiasis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 May 2017 New trial record
    • 17 May 2017 According to a Viamet Pharmaceuticals media release, data from this trial will be presented at The American Society for Microbiologys ASM Microbe 2017 Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top